【摘要】 目的探究博思清联合丙戊酸钠在急性躁狂症患者治疗的临床疗效和安全性。方法选取2018年2月至2019年2月该院收治60例急性躁狂症患者,随机分为两组,对照组给予丙戊酸钠治疗,观察组给予思清联合丙戊酸钠治疗,对比两组的临床治疗效果,分别于治疗后1周、4周和治疗后8周采用躁狂量表(BRMS)对两组的临床症状进行评价,并记录两组治疗期间不良反应的发生情况。结果观察组治疗总有效率为93.33%,明显高于对照组(P<0.05);两组的BRMS评分均明显低于治疗前,治疗后4周、治疗后8周观察组的BRMS评分均明显低于对照组(P<0.05)。结论在急性躁狂症患者的治疗中联合博思清与丙戊酸钠,能够明显提高临床疗效,改善患者临床症状,而且不会增加不良反应发生风险,值得推广应用。更多还原

【Abstract】 【Objective】To explore the efficacy and safety of brisking combined with valproate in the treatment of patients with acute mania.【Methods】From February 2018 to February 2019, 60 patients with acute mania in our hospital were randomly divided into two groups. The control group was treated with sodium valproate, the observation group was treated with brisking and sodium valproate, and the clinical treatment effect of the two groups was compared. The clinical symptoms of the two groups were evaluated with the Bech-Rafaelson Mania Scale(BRMS) 1 week, 4 weeks and 8 weeks after treatment, respectively. Adverse reactions were recorded during the treatment.【Results】The total effective rate of the observation group was 93.33%, which was significantly higher than that of the control group(P<0.05). The BRMS scores of the two groups were significantly lower than those before treatment. The BRMS scores of the observation group were obviously lower than those of the control group 4 weeks after treatment and 8 weeks after treatment(P<0.05).【Conclusion】The combination of brisking and sodium valproate in the treatment of patients with acute mania can significantly improve the clinical efficacy, improve the clinical symptoms of patients, and does not increase the risk of adverse reactions, so it is worthy of popularization and application.更多还原